Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science

BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science. Nestlé Health Science purchased 3,237,529 newly issued shares of Aimmune’s common stock at $30.27 per share on November 28, 2018, in a private placement transaction. The sale of shares was made pursuant to the terms of the Securities Purchase Agreement entered into on November 11, 2018, by Aimmune and Nestlé Health Science, as previously reported by Aimmune.

Additional details regarding the equity investment and strategic collaboration agreement can be found in Aimmune’s Form 8-K filed with the Securities and Exchange Commission on November 13, 2018.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Source: Aimmune Therapeutics, Inc.

Investors
Laura Hansen, Ph.D.
(650) 396-3814
lhansen@aimmune.com

Media
Alison Marquiss
(650) 376-5583
amarquiss@aimmune.com